Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid-Reference-Cited by-同舟云学术

Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid

Published:2023-10 Issue:10 Volume:29 Page:
ISSN:0909-752X
Container-title:Skin Research and Technology
language:en
Short-container-title:Skin Research and Technology

Author:

Manzo Margiotta Flavia¹,Fidanzi Cristian¹,Bevilacqua Matteo¹,Janowska Agata¹,Romanelli Marco¹,Manni Elisabetta¹

Affiliation:

1. Department of Dermatology University of Pisa Pisa Italy

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/srt.13488

Reference5 articles.

1. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity;Döpp R;J Am Acad Dermatol,2000

2. Interventions for bullous pemphigoid;Kirtschig G;Cochrane Database Syst Rev,2010

3. Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris

4. IgE autoantibodies in serum and skin of non‐bullous and bullous pemphigoid patients

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review;Journal of Clinical Medicine;2024-08-16

2. Successful dupilumab treatment in bullous pemphigoid complicated with subacute hematogenous disseminated tuberculosis: A case report;Skin Research and Technology;2024-07

3. Dapsone;Reactions Weekly;2024-05-04

4. Use of dupilumab for recalcitrant bullous pemphigoid: A case report;SAGE Open Medical Case Reports;2024-01